Skye Bioscience to Participate in SXSW Session on Obesity
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in obesity and metabolic health disorders treatments, has announced its participation in a significant South by Southwest (SXSW) panel discussion.
CEO Punit Dhillon will join a panel session titled 'Weighing in on Weight Loss Medicine' which will explore the future of obesity management beyond GLP-1 drugs. The session is scheduled for Monday, March 10, 2025, from 10:00 AM to 11:00 AM CT in Austin, TX.
SXSW, a renowned platform that combines technology, film, music, education, and culture, is known for promoting innovation and collaboration. The conference features dedicated tracks on health and medtech, showcasing breakthrough developments and innovative ideas in life sciences.
Skye Bioscience (Nasdaq: SKYE), una compagnia biofarmaceutica in fase clinica specializzata nel trattamento dell'obesità e dei disturbi metabolici, ha annunciato la sua partecipazione a un'importante discussione panel al South by Southwest (SXSW).
Il CEO Punit Dhillon parteciperà a una sessione panel intitolata 'Considerazioni sulla Medicina per la Perdita di Peso', che esplorerà il futuro della gestione dell'obesità oltre i farmaci GLP-1. La sessione è programmata per lunedì 10 marzo 2025, dalle 10:00 alle 11:00 CT ad Austin, TX.
SXSW, una piattaforma rinomata che combina tecnologia, film, musica, istruzione e cultura, è conosciuta per promuovere innovazione e collaborazione. La conferenza presenta percorsi dedicati alla salute e alla tecnologia medica, mettendo in mostra sviluppi rivoluzionari e idee innovative nelle scienze della vita.
Skye Bioscience (Nasdaq: SKYE), una empresa biofarmacéutica en etapa clínica especializada en el tratamiento de la obesidad y trastornos de la salud metabólica, ha anunciado su participación en una importante discusión en panel en el South by Southwest (SXSW).
El CEO Punit Dhillon se unirá a una sesión de panel titulada 'Reflexionando sobre la Medicina para la Pérdida de Peso', que explorará el futuro del manejo de la obesidad más allá de los medicamentos GLP-1. La sesión está programada para el lunes 10 de marzo de 2025, de 10:00 AM a 11:00 AM CT en Austin, TX.
SXSW, una plataforma reconocida que combina tecnología, cine, música, educación y cultura, es conocida por promover la innovación y la colaboración. La conferencia cuenta con pistas dedicadas a la salud y la tecnología médica, mostrando desarrollos innovadores y ideas revolucionarias en las ciencias de la vida.
스카이 바이오사이언스 (Nasdaq: SKYE), 비만 및 대사 건강 장애 치료를 전문으로 하는 임상 단계의 생명공학 회사가 사우스 바이 사우스웨스트 (SXSW) 패널 토론에 참여한다고 발표했습니다.
CEO 푸닛 딜론은 '체중 감량 약물에 대한 고찰'이라는 제목의 패널 세션에 참석하여 GLP-1 약물을 넘어서는 비만 관리의 미래를 탐구할 것입니다. 이 세션은 2025년 3월 10일 월요일, 오전 10시부터 오전 11시까지 CT에 텍사스주 오스틴에서 예정되어 있습니다.
SXSW는 기술, 영화, 음악, 교육 및 문화를 결합한 유명한 플랫폼으로, 혁신과 협력을 촉진하는 것으로 알려져 있습니다. 이 회의는 건강 및 의료 기술에 대한 전용 트랙을 제공하며, 생명 과학 분야의 혁신적인 발전과 아이디어를 선보입니다.
Skye Bioscience (Nasdaq: SKYE), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les traitements de l'obésité et des troubles de la santé métabolique, a annoncé sa participation à une discussion en panel significative lors du South by Southwest (SXSW).
Le PDG Punit Dhillon participera à une session de panel intitulée 'Réflexion sur les Médicaments pour la Perte de Poids', qui explorera l'avenir de la gestion de l'obésité au-delà des médicaments GLP-1. La session est prévue pour le lundi 10 mars 2025, de 10h00 à 11h00 CT à Austin, TX.
SXSW, une plateforme renommée qui combine technologie, cinéma, musique, éducation et culture, est connue pour promouvoir l'innovation et la collaboration. La conférence propose des pistes dédiées à la santé et à la technologie médicale, mettant en avant des développements révolutionnaires et des idées innovantes dans les sciences de la vie.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Fettleibigkeit und Stoffwechselerkrankungen spezialisiert hat, hat seine Teilnahme an einer bedeutenden South by Southwest (SXSW) Podiumsdiskussion bekannt gegeben.
CEO Punit Dhillon wird an einer Panel-Sitzung mit dem Titel 'Über Gewichtsverlustmedikamente nachdenken' teilnehmen, die die Zukunft des Fettleibigkeitsmanagements über GLP-1-Arzneimittel hinaus erkunden wird. Die Sitzung ist für Montag, den 10. März 2025, von 10:00 bis 11:00 Uhr CT in Austin, TX, geplant.
SXSW, eine renommierte Plattform, die Technologie, Film, Musik, Bildung und Kultur kombiniert, ist bekannt für die Förderung von Innovation und Zusammenarbeit. Die Konferenz bietet spezielle Tracks zu Gesundheit und Medizintechnik und präsentiert bahnbrechende Entwicklungen und innovative Ideen in den Lebenswissenschaften.
- None.
- None.
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs.
SXSW Conference Panel Session: "Weighing in on Weight Loss Medicine"
- Focus: The
- Date: Monday, March 10, 2025
- Time: 10:00 AM - 11:00 AM CT
- Location: Austin, TX
SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive meaningful conversations. Its dedicated tracks on health and medtech spotlight groundbreaking advancements and transformative ideas shaping the future of life sciences.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FAQ
What is the focus of Skye Bioscience's SXSW 2025 panel discussion?
When and where is Skye Bioscience's SXSW 2025 panel session scheduled?
What therapeutic areas does SKYE focus on as a clinical-stage company?
Which Skye Bioscience executive will be speaking at SXSW 2025?
